Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24200234 | 1.00 | MAPT (0.30) | MAPTEGFR | |
| SCHEMBL21561946 | 0.92 | MEN1 (0.33) | — | |
| SCHEMBL21562062 | 0.90 | KDM4E (0.36) | MAPT | |
| SCHEMBL25097868 | 0.89 | TBXAS1 (0.36) | MAPT | |
| SCHEMBL25908505 | 0.89 | TBXAS1 (0.36) | MAPT | |
| SCHEMBL23241461 | 0.86 | MEN1 (0.33) | — | |
| SCHEMBL23656723 | 0.83 | KDM4E (0.36) | MAPTEGFR | |
| SCHEMBL21562075 | 0.82 | MEN1 (0.33) | — | |
| SCHEMBL21455958 | 0.81 | MAPT (0.32) | MAPTEGFR | |
| SCHEMBL23656672 | 0.81 | TBXAS1 (0.36) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | MAPT 1251/4885EGFR 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.